Action PTIX PROTAGENIC THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Protagenic Therapeutics, Inc. Other OTC

Actions

PTIX

US74365N1037

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Protagenic Therapeutics, Inc.
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
Protagenic Therapeutics Achieves First Clinical Safety Milestone with Its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%
Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
PROTAGENIC THERAPEUTICS, INC.NEW : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director
PROTAGENIC THERAPEUTICS, INC.NEW : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)
PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
PROTAGENIC THERAPEUTICS, INC.NEW : Other Events (form 8-K)
PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PTIX
  4. Action PTIX
  5. Actualités Protagenic Therapeutics, Inc.
  6. Autres langues